Usefulness of early morning urine estrone-3-glucuronide assay in the monitoring ovarian secretory function in precocious puberty.
To evaluate the usefulness of the urinary estrone-3-glucuronide (EI-3-G) in the monitoring of the ovarian function in girls, we studied 11 girls with idiopathic central precocious puberty (ICPP) treated with LHRH analogs (LHRHa) for 2-5 years. Plasma LH, FSH, 17-beta-Estradiol (E2) levels, early morning urine (EMU) E1-3-G concentrations, were assessed before and 3, 6, 12 months after the onset of treatment. As expected, mean basal plasma LH, FSH and E2 concentrations, as well as mean basal EMU E1-3-G levels were significantly (p < 0.01) higher in patients studied than in normal, age matched, prepubertal controls. Three out of the 11 sexually advanced girls showed undetectable (< 15 pg/ml) basal plasma E2 values. On the contrary, in each patient studied, individual basal E1-3-G levels were higher than in normal age-matched prepubertal girls. LHRHa treatment significantly suppressed both basal and peak stimulated plasma gonadotropins, plasma E2 and EMU E1-3-G. However, while serum E2 levels were below the assay detection limit, not allowing to assess the degree of gonadal suppression, E1-3-G urinary concentrations were detectable in each subject treated, in the range of the normal prepubertal values. EMU E1-3-G determination seems to be a very sensitive and reliable approach to the monitoring of the effectiveness of LHRHa treatment in sexually advanced girls, allowing to detect very low estrogen concentrations and to achieve the desired ovarian suppression.
Bassi
F
F
Dipartimento di Fisiopatologia Clinica, Università di Firenze, Italy.
Bartolini
O
O
Neri
A S
AS
Gheri
R G
RG
Magini
A
A
Bucciantini
S
S
Bruni
V
V
D016022:Case-Control Studies; D002648:Child; D004958:Estradiol / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000652:urine*; D004970:Estrone / Q000031:analogs & derivatives* / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects; D010050:Ovarian Function Tests; D010053:Ovary / Q000378:metabolism*; D011629:Puberty, Precocious / Q000188:drug therapy / Q000503:physiopathology / Q000652:urine*
D004966:Estrogens, Conjugated (USP); C015856:estrone-3-glucuronide; D004970:Estrone; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone